What is PRME's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.72B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for PRME?

P/E (TTM) is n/a and 52-week range is $2.67 to $6.65 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s PRME figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for PRME?

The company profile lists revenue (TTM) near $4M, net income (TTM) near $-19.16B, EPS (TTM) near $-1.09 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Prime Medicine Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Cambridge, Massachusetts, US, 180.6M shares outstanding, ISIN US74168J1016 when available from company profile and filing metadata.

Prime Medicine Inc

$PRME

Health Care · Biotechnology

IR Run Scenarios

$3.99

+11.45%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 146 full-time employees. The company went IPO on 2022-10-20. The company deploys its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. The company is advancing a set of high-value programs across its core areas of focus (hematology, immunology and oncology, liver, and lung). These include ex vivo hematopoietic stem cell (HSC) programs for the treatment of p47phox chronic granulomatous disease CGD and X-linked CGD; a lipid nanoparticle (LNP) Prime Editor for the treatment of Wilson’s Disease; a LNP or adeno-associated virus Prime Editors for the treatment of cystic fibrosis; and ex vivo T-cell therapies. PM359, its product candidate within its hematology, immunology and oncology area of focus, targets the p47phox variant of CGD. Its PM577 comprises a Prime Editor encapsulated as RNA cargo in a liver-targeted LNP.

Employees

146

Website

primemedicine.com/

IPO

2022-10-20

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)